Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adelaide A Hebert

Showing results (131-140 of 150) with videos related to

Pageof 15
Sort By:
Journal of the American Academy of Dermatology|May 18, 2025
Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitisRobert Bissonnette, Linda Stein Gold, Leon Kircik, et al.
The New England Journal of Medicine|November 5, 2025
Oral Icotrokinra for Plaque Psoriasis in Adults and AdolescentsRobert Bissonnette, Jennifer Soung, Adelaide A Hebert, et al.
The Journal of Investigative Dermatology|January 8, 2004
A novel GJB2 (connexin 26) mutation, F142L, in a patient with unusual mucocutaneous findings and deafnessChester W Brown, Moise L Levy, Catherine M Flaitz, et al.
Journal of the American Academy of Dermatology|May 22, 2024
Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trialsJonathan I Silverberg, Lawrence F Eichenfield, Adelaide A Hebert, et al.
Dermatology and Therapy|October 24, 2025
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III TrialsKim A Papp, James Q Del Rosso, Mark G Lebwohl, et al.
The Journal of Dermatological Treatment|June 11, 2026
Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summaryAndrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
Journal of the American Academy of Dermatology|July 16, 2016
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adultsAmy S Paller, Wynnis L Tom, Mark G Lebwohl, et al.
Pediatric Dermatology|February 21, 2025
Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled TrialLawrence F Eichenfield, Rocco Serrao, Vimal H Prajapati, et al.
Journal of the American Academy of Dermatology|January 22, 2024
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trialAndrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
The Journal of Dermatological Treatment|June 11, 2026
Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summaryEric Simpson, Lawrence F Eichenfield, Kim A Papp, et al.
Pageof 15

Showing results (131-140 of 150) with videos related to

Sort By:
Pageof 15
Journal of the American Academy of Dermatology|May 18, 2025
Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitisRobert Bissonnette, Linda Stein Gold, Leon Kircik, et al.
The New England Journal of Medicine|November 5, 2025
Oral Icotrokinra for Plaque Psoriasis in Adults and AdolescentsRobert Bissonnette, Jennifer Soung, Adelaide A Hebert, et al.
The Journal of Investigative Dermatology|January 8, 2004
A novel GJB2 (connexin 26) mutation, F142L, in a patient with unusual mucocutaneous findings and deafnessChester W Brown, Moise L Levy, Catherine M Flaitz, et al.
Journal of the American Academy of Dermatology|May 22, 2024
Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trialsJonathan I Silverberg, Lawrence F Eichenfield, Adelaide A Hebert, et al.
Dermatology and Therapy|October 24, 2025
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III TrialsKim A Papp, James Q Del Rosso, Mark G Lebwohl, et al.
The Journal of Dermatological Treatment|June 11, 2026
Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summaryAndrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
Journal of the American Academy of Dermatology|July 16, 2016
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adultsAmy S Paller, Wynnis L Tom, Mark G Lebwohl, et al.
Pediatric Dermatology|February 21, 2025
Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled TrialLawrence F Eichenfield, Rocco Serrao, Vimal H Prajapati, et al.
Journal of the American Academy of Dermatology|January 22, 2024
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trialAndrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
The Journal of Dermatological Treatment|June 11, 2026
Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summaryEric Simpson, Lawrence F Eichenfield, Kim A Papp, et al.
Pageof 15